Evidence map›Paper›PMID 33600060›Full record

Trial reportPediatrics international : official journal of the Japan Pediatric Society2021

Randomized trial of different initial intravenous immunoglobulin regimens in Kawasaki disease.

Lan He, Fang Liu, Weili Yan, Min Huang, Meirong Huang, Lijian Xie, Ying Guo, Xinyi Xu, Chen Chu, Lin Wu and 8 more

Registry-linked trialOpen access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pediatrics international : official journal of the Japan Pediatric Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02439996 (Different Doses of IVIG for Kawasaki Disease), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02439996 phase3completednot on this map

Different Doses of IVIG for Kawasaki Disease: a Multicentre, Prospective, Randomised Trial

TypeinterventionalSponsorChildren's Hospital of Fudan UniversityRan2014 to 2016Enrolled404ConditionsKawasaki DiseaseArmsIVIG (1g/kg,once), IVIG (1g/kg,twice), IVIG (2g/kg.once)
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Intravenous immunoglobulin for the treatment of Kawasaki disease.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Review
  3. Review
  4. Intravenous immunoglobulins (IVIG) in severe/critical COVID-19 adult patients.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Lan HePediatric Heart Center, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Fang LiuPediatric Heart Center, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Weili YanDepartment of Clinical Epidemiology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Min HuangCardiovascular Department, Shanghai Children's Hospital of Shanghai Jiaotong University, Shanghai, China.
Meirong HuangCardiovascular Department, Shanghai Children's Medical Center of Shanghai Jiaotong University, Shanghai, China.
Lijian XieCardiovascular Department, Shanghai Children's Hospital of Shanghai Jiaotong University, Shanghai, China.
Ying GuoCardiovascular Department, Shanghai Children's Medical Center of Shanghai Jiaotong University, Shanghai, China.
Xinyi XuCardiovascular Department, Shanghai Children's Medical Center of Shanghai Jiaotong University, Shanghai, China.
Chen ChuPediatric Heart Center, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Lin WuPediatric Heart Center, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Xuecun LiangPediatric Heart Center, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Shuna SunPediatric Heart Center, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Feng WangPediatric Heart Center, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Lu ZhaoPediatric Heart Center, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Quming ZhaoPediatric Heart Center, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Xiaojing MaPediatric Heart Center, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Liping XiePediatric Heart Center, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Guoying HuangPediatric Heart Center, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.ORCID https://orcid.org/0000-0001-6002-2226
Children's Hospital of Fudan University · CNShanghai Children's Medical Center · CN

Funding

Chinese Academy of Medical Sciences Research Unit 2018RU002Joint Research Projects of Emerging Cutting-edge Technologies of Shanghai Municipal Hospitals SHDC12013106Science and Technology Commission of Shanghai Municipality 15ZR1404300
6 · The paper itself

Abstract

backgroundWe aimed to assess the efficacy of different initial intravenous immunoglobulin (IVIG) regimens in Kawasaki disease (KD) patients to find more cost-effective therapy options.

methodsA multicenter, open-label, blind-endpoint randomized controlled trial was conducted from January 2014 to December 2015. Patients with KD, within 10 days of illness, were randomly assigned to receive different IVIG regimens (Group A, 2 g/kg once; Group B, 1 g/kg for 2 consecutive days; Group C, 1 g/kg once) and aspirin 30mg/kg/d. Primary outcomes included hours to defervescence and development of coronary artery lesions during the study period. Major secondary outcomes included total fever days, total dose of IVIG, changes of laboratory data, length of stay, and hospitalization expenses. (ClinicalTrials.gov: NCT02439996).

resultsA total of 404 patients underwent randomization. No difference was found in the outcomes of defervescence among three groups at 6, 12, 24, and 36 hours after completion of initial IVIG infusion. There were no differences in the incidence of coronary artery lesions during the study period (at week 2, month 1, month 3, and month 6 of illness), changes of laboratory data, total fever days, and length of stay. Group C patients had the lowest total dose of IVIG (mean: 1.2 vs 2.2 vs 2.1 g/kg; P < 0.001) and hospitalization expenses (mean: 8443.8 vs 10798.4 vs 11011.4 Chinese Yuan; P < 0.001) than other two groups.

conclusionsA single dose of 1g/kg IVIG is a low-cost treatment with the same efficacy as 2 g/kg IVIG and can be an option for the initial therapy of KD patients.

Indexed as

Immunoglobulins, IntravenousMucocutaneous Lymph Node SyndromeAspirinFeverHumansInfantAspirinImmunoglobulins, Intravenouscoronary aneurysmcost-benefit analysisimmunoglobulinsintravenousmucocutaneous lymph node syndrometreatment outcome

Identifiers

PMID33600060
PMCPMC8362187
OpenAlexW3133213534

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.